Table 2.

Prevalence ofHFEC282Y and H63D genotypes according to race or ethnic group.*

C282Y/C282YC282Y/H63DH63D/H63DC282Y/+H63D/++/+
Race or ethnic groupTotal no. of participantsNo.Prevalence, % (95% CI)No.Prevalence, % (95% CI)No.Prevalence, % (95% CI)No.Prevalence, % (95% CI)No.Prevalence, % (95% CI)No.Prevalence, % (95% CI)
*All participants with complete data on HFE C282Y and H63D mutations, TfS, and SF levels are included, with the exception of 1457 participants who reported hearing about the study exclusively from a participating family member. Rates of prevalence were derived with Hardy-Weinberg proportions in the five groups of participants not homozygous for the C282Y mutation within each racial or ethnic group. Race or ethnic group was self-reported. 
CI indicates confidence interval. 
Reprinted with permission from Adams PC et al. N Engl J Med. 2005;352:1769–1778. 29  
White 44,082 281 0.44 (0.42–0.47) 908 2.0 (2.0–2.1) 1029 2.4 (2.3–2.4) 4548 10 (10–11) 10,537 24 (24–24) 26,779 61 (60–61) 
Native American 648 0.11 (0.061–0.20) 0.77 (0.56–1.1) 1.3 (0.98–1.8) 35 5.7 (4.2–7.7) 128 20 (17–22) 470 72 (69–76) 
Hispanic 12,459 0.027 (0.022–0.032) 48 0.33 (0.30–0.37) 154 1.1 (0.98–1.1) 351 2.9 (2.6–3.2) 2199 18 (18–19) 9700 78 (77–78) 
Black 27,124 0.014 (0.012–0.017) 35 0.071 (0.065–0.078) 30 0.089 (0.081–0.097) 605 2.3 (2.1–2.5) 1520 5.7 (5.4–6.0) 24,930 92 (92–92) 
Pacific Islander 698 0.012 (0.0043–0.032) 0.096 (0.055–0.17) 0.20 (0.12–0.32) 15 2.0 (1.2–3.4) 62 8.4 (6.6–11) 621 89 (87–91) 
Asian 12,772 0.000039 (0.000015–0.0001) 0.0055 (0.0029–0.0093) 29 0.20 (0.17–0.22) 16 0.12 (0.074–0.19) 1070 8.4 (8.0–8.9) 11,657 91 (91–92) 
Multiple/unknown 1928 — 19 — 21 — 111 — 313 — 1458 — 
All 99,711 299 — 1017 — 1270 — 5681 — 15,829 — 75,615 — 
C282Y/C282YC282Y/H63DH63D/H63DC282Y/+H63D/++/+
Race or ethnic groupTotal no. of participantsNo.Prevalence, % (95% CI)No.Prevalence, % (95% CI)No.Prevalence, % (95% CI)No.Prevalence, % (95% CI)No.Prevalence, % (95% CI)No.Prevalence, % (95% CI)
*All participants with complete data on HFE C282Y and H63D mutations, TfS, and SF levels are included, with the exception of 1457 participants who reported hearing about the study exclusively from a participating family member. Rates of prevalence were derived with Hardy-Weinberg proportions in the five groups of participants not homozygous for the C282Y mutation within each racial or ethnic group. Race or ethnic group was self-reported. 
CI indicates confidence interval. 
Reprinted with permission from Adams PC et al. N Engl J Med. 2005;352:1769–1778. 29  
White 44,082 281 0.44 (0.42–0.47) 908 2.0 (2.0–2.1) 1029 2.4 (2.3–2.4) 4548 10 (10–11) 10,537 24 (24–24) 26,779 61 (60–61) 
Native American 648 0.11 (0.061–0.20) 0.77 (0.56–1.1) 1.3 (0.98–1.8) 35 5.7 (4.2–7.7) 128 20 (17–22) 470 72 (69–76) 
Hispanic 12,459 0.027 (0.022–0.032) 48 0.33 (0.30–0.37) 154 1.1 (0.98–1.1) 351 2.9 (2.6–3.2) 2199 18 (18–19) 9700 78 (77–78) 
Black 27,124 0.014 (0.012–0.017) 35 0.071 (0.065–0.078) 30 0.089 (0.081–0.097) 605 2.3 (2.1–2.5) 1520 5.7 (5.4–6.0) 24,930 92 (92–92) 
Pacific Islander 698 0.012 (0.0043–0.032) 0.096 (0.055–0.17) 0.20 (0.12–0.32) 15 2.0 (1.2–3.4) 62 8.4 (6.6–11) 621 89 (87–91) 
Asian 12,772 0.000039 (0.000015–0.0001) 0.0055 (0.0029–0.0093) 29 0.20 (0.17–0.22) 16 0.12 (0.074–0.19) 1070 8.4 (8.0–8.9) 11,657 91 (91–92) 
Multiple/unknown 1928 — 19 — 21 — 111 — 313 — 1458 — 
All 99,711 299 — 1017 — 1270 — 5681 — 15,829 — 75,615 — 
Close Modal

or Create an Account

Close Modal
Close Modal